After BRAG2 binding to phosphorylated EGFR, ARF6 is activated in breast cancer cells, leading to the formation of invadopodia with recruitment of Cortactin, Paxillin and the ARF GAP ASAP1 (Onodera et al., 2005; Morishige et al., 2008). Here, ARF6 is linked to breast carcinoma.